Switching from cinacalcet to ebocalcet in secondary hyperparathyroidism patients during hemodialysis.

Switching from cinacalcet to ebocalcet in secondary hyperparathyroidism patients during hemodialysis. - Switching from cinacalcet to ebocalcet

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000036862

Enrollment

Registered

2019-07-01

Start date

2018-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism

Interventions

Evocalcet was started with an initial dose of 1 mg / day orally on the day after cinacalcet discontinuation. The amount of evocalcet was then adjusted so that parathyroid hormone was in the 60-240 ra

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Three weekly hemodialysis patients of seconda ry hyperparathyroidism who are orally taking Cinacalcet.

Exclusion criteria

Exclusion criteria: Patients with malignant tumors

Design outcomes

Primary

Measure	Time frame
Noninferiority of ebocalcet to cinacalcet on serum parathyroid hormone suppression after 12 months	—

Secondary

Measure	Time frame
Evaluation of safety of ebocalcet, especially including hypocalcemia	—

Countries

Japan

Contacts

Public ContactRyoichi Miyazaki

Fujita Memorial Hospital Department of Internal Medicine

ryoichi@mitene.or.jp0776-21-1277

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026